Lixin  Li

Dr. Lixin Li


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JZJoseph Zhou
Joseph Zhou
SMScott Massey
Scott Massey
DSDarren Story
Darren Story
Lixin  Li Lixin Li
Lixin Li
Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years. The United Kingdom Prospective Diabetic Study (UKPDS) has shown metformin to improve mortality rates in diabetes patients, and recent studies suggest metformin has additional effects in treating cancer, obesity, nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic syndrome. Metformin has also been shown to alleviate weight gain associated with antipsychotic medication. Metformin has recently been extensively studied and emerging evidence suggests metformin decreases hepatocyte triglyceride accumulation in NAFLD and prevents liver tumorigenesis. Interestingly, studies have also shown metformin reduces visceral fat, suppresses white-adipose-tissue (WAT) extracellular matrix remodeling, and inhibits obesity-induced inflammation. However, clinical evidence for using metformin to treat NAFLD, cancer, metabolic syndrome, or to prevent hepatocellular carcinoma in NAFLD patients is lacking. This review therefore addresses the potential beneficial effects of metformin on NAFLD, its role in protecting against cardiac ischemia–reperfusion (I/R) injury, atherosclerosis, glucotoxicity, and lipotoxicity induced oxidative and ER stress in pancreatic β-cell dysfunction, as well as its underlying molecular mechanisms of action.

1 March 2004 in Diabetologia
Verified
Journal Article
Closed access
PDF file
QWQ. Wang
Q. Wang
Lixin  Li Lixin Li
Lixin Li
EXE. Xu
E. Xu
VWV. Wong
V. Wong
CRC. Rhodes
C. Rhodes
PBPatricia. L. Brubaker
Patricia. L. Brubaker

19 May 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
Lixin  Li Lixin Li
Lixin Li
WEW. El-Kholy
W. El-Kholy
CRC. J. Rhodes
C. J. Rhodes
PBPatricia. L. Brubaker
Patricia. L. Brubaker

1 March 2001 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Lixin  Li Lixin Li
Lixin Li
FSFrank Skorpen
Frank Skorpen
KEKjartan Egeberg
Kjartan Egeberg
IJIngrid Hals Jørgensen
Ingrid Hals Jørgensen
VGValdemar Grill
Valdemar Grill

20 June 2016 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
JZJ. Y. Zhou
J. Y. Zhou
BXB. Xu
B. Xu
JLJ. Lopes
J. Lopes
JBJ. Blamoun
J. Blamoun
Lixin  Li Lixin Li
Lixin Li

Verified
Journal Article
Open access
PDF file
LPLeela Paladugu
Leela Paladugu
AGAbeer Gharaibeh
Abeer Gharaibeh
NKNivya Kolli
Nivya Kolli
CLCameron Learman
Cameron Learman
THTia C. Hall
Tia C. Hall
Gary DunbarGary Dunbar
Gary Dunbar
Recent clinical and epidemiological studies support the contention that diabetes mellitus (DM) is a strong risk factor for the development of Alzheimer’s disease (AD). The use of insulin cell toxin, streptozotocin (STZ), when injected into the lateral ventricles, develops an insulin resistant brain state (IRBS) and represents a non-transgenic, or sporadic AD model (SAD), with several AD-like neuropathological features. The present study explored the effects of an anti-diabetic drug, liraglutide (LIR), in reversing major pathological hallmarks in the prodromal disease stage of both the 5xFAD transgenic and SAD mouse models of AD. Three-month-old 5xFAD and age-matched wild type mice were given a single intracerebroventricular (i.c.v) injection of STZ or vehicle (saline) and were subsequently treated with LIR, intraperitoneally (IP), once a day for 30 days. The extent of neurodegeneration, Aβ plaque load, and key proteins associated with the insulin signaling pathways were measured using Western blot and neuroinflammation (via immunohistological assays) in the cortical and hippocampal regions of the brain were assessed following a series of behavioral tests used to measure cognitive function after LIR or vehicle treatments. Our results indicated that STZ significantly increased neuroinflammation, Aβ plaque deposition and disrupted insulin signaling pathway, while 25 nmol/kg LIR, when injected IP, significantly decreased neuroinflammatory responses in both SAD and 5xFAD mice before significant cognitive changes were observed, suggesting LIR can reduce early neuropathology markers prior to the emergence of overt memory deficits. Our results indicate that LIR has neuroprotective effects and has the potential to serve as an anti-inflammatory and anti-amyloid prophylactic therapy in the prodromal stages of AD.